Standout Papers

Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carci... 2021 2026 2022 2024162
  1. Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma (EV‑201): a multicentre, single-arm, phase 2 trial (2021)
    Evan Y. Yu, Daniel P. Petrylak et al. The Lancet Oncology

Immediate Impact

5 by Nobel laureates 11 from Science/Nature 63 standout
Sub-graph 1 of 22

Citing Papers

Renal cell carcinoma
2024 Standout
T-cell-engaging bispecific antibodies in cancer
2023 Standout
5 intermediate papers

Works of Mark N. Stein being referenced

Adjuvant everolimus after surgery for renal cell carcinoma (EVEREST): a double-blind, placebo-controlled, randomised, phase 3 trial
2023
Results of an ongoing phase 1/2a dose escalation study of HPN424, a tri-specific half-life extended PSMA-targeting T-cell engager, in patients with metastatic castration-resistant prostate cancer (mCRPC).
2021
and 2 more

Author Peers

Author Last Decade Papers Cites
Mark N. Stein 2029 2434 2261 239 5.6k
Young Kwang Chae 1813 3005 2481 263 6.1k
Lukas C. Heukamp 1655 1852 3381 170 6.0k
Kenji Sugio 3236 3124 2698 276 7.0k
Shoji Natsugoe 1404 2446 2013 195 5.5k
Jianping Xiong 1601 1914 2009 186 4.8k
Davide Melisi 1242 3347 2373 158 5.7k
Michael J. Pishvaian 1095 3666 1907 211 5.6k
Jian Zhou 978 1949 2376 213 6.2k
Begoña Mellado 2130 1861 1931 178 4.6k
Maurizio Martini 1041 1889 2283 277 6.3k

All Works

Loading papers...

Rankless by CCL
2026